Bayer Submits Supplemental New Drug Application for KERENDIA® (Finerenone) to Treat Heart Failure with Preserved or Mildly Reduced Ejection Fraction

Bayer announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for KERENDIA® (finerenone...

January 13, 2025 | Monday | News
QIAcuity Digital PCR Expands Capacity to 12 Targets Simultaneously with New Software Update and High Multiplex PCR Kit

  QIAcuity digital PCR now offers ability for simultaneous detection of up to 12 targets from one biological sample, a more than two-fold inc...

January 13, 2025 | Monday | News
Revvity Secures FDA Clearance for EUROIMMUN’s Groundbreaking Free Testosterone Test

-Revvity, Inc.  announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemilu...

January 13, 2025 | Monday | News
Corcept Therapeutics Submits NDA to FDA for Relacorilant to Treat Cushing’s Syndrome

Corcept Therapeutics, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab...

January 02, 2025 | Thursday | News
Hoth Therapeutics Secures Exclusive Patent License from VA and Emory University to Tackle Obesity and Related Diseases

Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Ma...

December 27, 2024 | Friday | News
Keymed Biosciences Secures NMPA Approval for Stapokibart in Treating Chronic Rhinosinusitis with Nasal Polyposis

Keymed Biosciences Inc. announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Appl...

December 27, 2024 | Friday | News
Proton Intelligence Secures $6.95M Seed Funding to Advance Continuous Potassium Monitoring for Cardio-Kidney-Metabolic Care

Proton Intelligence Inc., developing the first-ever Continuous Potassium Monitoring (CKM™) platform,  announced the closing of its $6.95 milli...

December 26, 2024 | Thursday | News
Fujirebio and Eisai Forge Partnership to Advance Blood-Based Diagnostics for Neurodegenerative Diseases

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Cha...

December 26, 2024 | Thursday | News
HKBU and Shanghai Sixth People's Hospital Pioneer Breakthrough Treatment for Rare Bone Disease XLH

A research led by Hong Kong Baptist University (HKBU) and the Shanghai Sixth People's Hospital Affiliated to School of Medicine at Shanghai Jiao ...

December 23, 2024 | Monday | News
Saudi Arabia’s KFSHRC Launches MENA’s First Advanced Hematology Diagnostics Laboratory

King Faisal Specialist Hospital & Research Centre (KFSHRC) inaugurated the Advanced Hematology Diagnostics Laboratory under the patronage of Deputy C...

December 20, 2024 | Friday | News
Shuttle Pharmaceuticals and UCSF Collaborate in the U.S. to Advance Theranostic Innovations for Prostate Cancer

Shuttle Pharmaceuticals Holdings, Inc.  a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer ...

December 20, 2024 | Friday | News
Smith+Nephew Expands CORI◊ Surgical System Portfolio with FDA-Cleared CORIOGRAPH Pre-Op Planning for Hip Arthroplasty

Latest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons Smith+Nephew (LSE:SN, NYSE:SNN),...

December 20, 2024 | Friday | News
Advancing Healthspan for All: Dr. Mehmood Khan Spotlights Aging Science Trends for 2025

  In an exclusive interview with BioPharma Boardroom, Dr. Mehmood Khan, Chief Executive Officer of Hevolution Foundation, shares insights into the tr...

December 12, 2024 | Thursday | News
Zepbound® (Tirzepatide) Outperforms Wegovy® (Semaglutide) in Phase 3b SURMOUNT-5 Trial, Demonstrating Superior Weight Loss

Eli Lilly and Company (NYSE: LLY) announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound® ...

December 09, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close